All Stories
Follow
Subscribe to Marseille-Kliniken AG

Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Preliminary revenues at EUR 201.4 million for fiscal 2004/2005 slightly above previous year's level - Earnings per share improve EUR 0.08 to EUR 0.73 - Expansion of core division Nur

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
29.09.2005
Berlin, September 29, 2005 - On the basis of preliminary figures for
the fiscal year 2004/05, the Marseille-Kliniken AG (Prime Standard,
ISIN DE 0007783003, MKA) was able to slightly expand sales to EUR
201.4 million (previous year EUR 200.1 million). The result from
ordinary operations improved substantially from - EUR 8.8 million in
the previous year to + EUR 8.8 million. The earnings for the fiscal
year pursuant to DVFA/SG (HGB) amounted to EUR 7.6 million compared
with EUR 7.5 million in the previous year. According to IFRS a
consolidated profit pursuant to DVFA/SG of EUR 8.9 million (previous
year: EUR 7.9 million) results for the period under review. This
corresponds to an increase in earnings per share by EUR 0.08 to EUR
0.73 (previous year: EUR 0.65).
The trend in revenues and earnings in the fiscal year 2004/2005
reflects the different market conditions in the segments Nursing and
Rehabilitation. In Rehabilitation, the utilization rate was
stabilized at last year’s level and amounted to 76.6%. However, the
division still burdens the revenues and earnings for the entire
group. The bed capacity declined by 100 beds from 1,772 to 1,672.
Accordingly, revenues declined by additional EUR 2.4 million from EUR
53.1 million in the previous year and thus amounted to EUR 50.7
million in the period under review. With a loss of - EUR 3.6 million
(previous year: - EUR 4.0 million) the division continued to weigh on
the overall results.
The main driver of growth still remains the stable profitability of
the core segment Nursing, which accounts for 78% of the overall bed
capacity. With revenues of EUR 150.7 million in this segment the
Marseille-Kliniken AG recorded a growth of EUR 3.7 million compared
with EUR 147.0 million one year ago. The earnings pursuant to DVFA/SG
(HGB) stood at EUR 11.2 million and thus remained at previous year's
level (pervious year: EUR 11.5 million). Due to the start-up time of
four new facilities and renovation work at two other facilities the
capacity utilization rate of 90.7% did not quite reach previous
year's utilization rate of 94.3%. Accordingly, the Group's capacity
utilization rate amounted to 87.5%, which is below the level of 90.0%
achieved one year ago.
The expansion of the Nursing division is being further progressed.
During the period under review two new facilities with 238 beds were
opened in Dresden and in Hennigsdorf/Berlin. In addition, the core
division Nursing was complemented by the service segment "Assisted
Living". In the current fiscal year Marseille-Kliniken AG has started
to offer services for the elderly in three sets of buildings with
more than 750 apartments. The expansion of the service segment
"Assisted Living" is a logical step for the Marseille-Kliniken AG in
its broadening of the range of services offered to the elderly. The
company already expects a significant earnings contribution from the
new service division in the current fiscal year suggesting higher
returns than stationary care.
Overall, the number of facilities rose from 58 in the past fiscal
year to currently 60. The number of beds increased slightly from
7,512 to 7,573 due to the new facilities in the Nursing division
despite the decline in the Rehabilitation segment. With two new
facilities in Dusseldorf and Hamburg and the expansion of the service
division "Assisted Living", the bed capacity will increase by 1,100
beds in the current fiscal year.
The Marseille-Kliniken AG will also continue its shareholder-friendly
distribution policy this year. The Management Board will recommend
the Supervisory Board and the Annual General Meeting to resolve a
dividend of EUR 0.40 per share.
Following the approval of the annual financial statements by the
Supervisory Board the annual report for the fiscal year 2004/2005
will be published in mid-October.
End of the ad hoc release
end of announcement                               euro adhoc 29.09.2005 19:04:38

Further inquiry note:

Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401
or
Hillermann Consulting
Christian Hillermann
Tel: +49 40 414 069 13
Fax: +49 40 414 069 14

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen: Berliner Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bremer Wertpapierbörse (BWB) / free trade
Hamburger Wertpapierbörse / official dealing
Frankfurter Wertpapierbörse / official dealing

Original content of: Marseille-Kliniken AG, transmitted by news aktuell

More stories: Marseille-Kliniken AG
More stories: Marseille-Kliniken AG